Matches in SemOpenAlex for { <https://semopenalex.org/work/W2241288537> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2241288537 endingPage "5556" @default.
- W2241288537 startingPage "5556" @default.
- W2241288537 abstract "5556 Background: Pazopanib is a small molecule tyrosine kinase inhibitor of VEGFR1-3, c-kit, and PDGFR. Nasopharyngeal carcinoma (NPC) is endemic in Asia and angiogenesis is important for growth and progression. We hypothesized that anti-angiogenesis with pazopanib would be effective in NPC. Methods: An open-label monotherapy study of pazopanib in patients with WHO type II/III NPC and metastatic/recurrent disease who failed at least one line of chemotherapy was done. A Simon's optimal 2-stage design was employed. Patients with ECOG 0-2 and adequate organ function were treated with pazopanib 800 mg daily on a 21-day cycle. The primary endpoint was the best overall response (CR/PR/SD) achieved after 12 weeks of treatment. Secondary endpoints included toxicity and progression-free survival. Dynamic-contrast enhanced computed tomography (DCE-CT) of target lesions and pharmacokinetics (PK) of pazopanib was also done. Results: Thirty-three patients were accrued (August 2007-August 2009). All patients were ECOG 0-1 with median age of 50 years (range 36-68). Patients had received median of 3 (range 1-7) prior chemotherapy. There were 2 (6.1 %) partial responses, 16 (48.5%) stable disease, 14 (42.4%) progressive disease, 4 (12.1%) not evaluable for response (2 deaths, 2 declined further evaluation), giving a clinical benefit rate of 54.5% (95% CI 38.0-70.2). Fifteen patients (45%) received more than 5 cycles of treatment, 6 (18.2%) had PR/SD that lasted at least 6 months and one patient remains on treatment. One patient each died from epistaxis and myocardial infarction before response evaluation. Grade 3/4 toxicities included fatigue (15.2%), hand-foot syndrome (15.2%), anorexia (9.1%), diarrhea (6.1%), vomiting (6.1%), dehydration (3%), hypertension (3%), hyponatremia (6%), neutropenic fever (3%), proteinuria (3%), pericardial effusion (3%). Serial DCE-CT scans demonstrate significant reductions in tumor blood flow, permeability surface area product, and fractional intravascular blood volume. Conclusions: Pazopanib appears to be active in nasopharyngeal carcinoma with an acceptable toxicity profile. Further PK/PD analyzes are ongoing. No significant financial relationships to disclose." @default.
- W2241288537 created "2016-06-24" @default.
- W2241288537 creator A5003744229 @default.
- W2241288537 creator A5019107660 @default.
- W2241288537 creator A5023390360 @default.
- W2241288537 creator A5035273217 @default.
- W2241288537 creator A5047867718 @default.
- W2241288537 creator A5072637653 @default.
- W2241288537 creator A5073819873 @default.
- W2241288537 creator A5078319904 @default.
- W2241288537 creator A5078667232 @default.
- W2241288537 creator A5080736692 @default.
- W2241288537 date "2010-05-20" @default.
- W2241288537 modified "2023-10-16" @default.
- W2241288537 title "A phase II study of GW786034 (pazopanib) in Asian patients with recurrent/metastatic undifferentiated nasopharyngeal carcinoma." @default.
- W2241288537 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.5556" @default.
- W2241288537 hasPublicationYear "2010" @default.
- W2241288537 type Work @default.
- W2241288537 sameAs 2241288537 @default.
- W2241288537 citedByCount "5" @default.
- W2241288537 countsByYear W22412885372012 @default.
- W2241288537 countsByYear W22412885372017 @default.
- W2241288537 crossrefType "journal-article" @default.
- W2241288537 hasAuthorship W2241288537A5003744229 @default.
- W2241288537 hasAuthorship W2241288537A5019107660 @default.
- W2241288537 hasAuthorship W2241288537A5023390360 @default.
- W2241288537 hasAuthorship W2241288537A5035273217 @default.
- W2241288537 hasAuthorship W2241288537A5047867718 @default.
- W2241288537 hasAuthorship W2241288537A5072637653 @default.
- W2241288537 hasAuthorship W2241288537A5073819873 @default.
- W2241288537 hasAuthorship W2241288537A5078319904 @default.
- W2241288537 hasAuthorship W2241288537A5078667232 @default.
- W2241288537 hasAuthorship W2241288537A5080736692 @default.
- W2241288537 hasConcept C121608353 @default.
- W2241288537 hasConcept C126322002 @default.
- W2241288537 hasConcept C141071460 @default.
- W2241288537 hasConcept C143998085 @default.
- W2241288537 hasConcept C203092338 @default.
- W2241288537 hasConcept C2776694085 @default.
- W2241288537 hasConcept C2778439243 @default.
- W2241288537 hasConcept C2778822529 @default.
- W2241288537 hasConcept C2778997737 @default.
- W2241288537 hasConcept C2779490328 @default.
- W2241288537 hasConcept C2779984678 @default.
- W2241288537 hasConcept C2780739268 @default.
- W2241288537 hasConcept C31760486 @default.
- W2241288537 hasConcept C509974204 @default.
- W2241288537 hasConcept C535046627 @default.
- W2241288537 hasConcept C71924100 @default.
- W2241288537 hasConcept C90924648 @default.
- W2241288537 hasConceptScore W2241288537C121608353 @default.
- W2241288537 hasConceptScore W2241288537C126322002 @default.
- W2241288537 hasConceptScore W2241288537C141071460 @default.
- W2241288537 hasConceptScore W2241288537C143998085 @default.
- W2241288537 hasConceptScore W2241288537C203092338 @default.
- W2241288537 hasConceptScore W2241288537C2776694085 @default.
- W2241288537 hasConceptScore W2241288537C2778439243 @default.
- W2241288537 hasConceptScore W2241288537C2778822529 @default.
- W2241288537 hasConceptScore W2241288537C2778997737 @default.
- W2241288537 hasConceptScore W2241288537C2779490328 @default.
- W2241288537 hasConceptScore W2241288537C2779984678 @default.
- W2241288537 hasConceptScore W2241288537C2780739268 @default.
- W2241288537 hasConceptScore W2241288537C31760486 @default.
- W2241288537 hasConceptScore W2241288537C509974204 @default.
- W2241288537 hasConceptScore W2241288537C535046627 @default.
- W2241288537 hasConceptScore W2241288537C71924100 @default.
- W2241288537 hasConceptScore W2241288537C90924648 @default.
- W2241288537 hasIssue "15_suppl" @default.
- W2241288537 hasLocation W22412885371 @default.
- W2241288537 hasOpenAccess W2241288537 @default.
- W2241288537 hasPrimaryLocation W22412885371 @default.
- W2241288537 hasRelatedWork W2085866999 @default.
- W2241288537 hasRelatedWork W2111879300 @default.
- W2241288537 hasRelatedWork W2133354058 @default.
- W2241288537 hasRelatedWork W2592092676 @default.
- W2241288537 hasRelatedWork W2620160838 @default.
- W2241288537 hasRelatedWork W2889701300 @default.
- W2241288537 hasRelatedWork W3029439632 @default.
- W2241288537 hasRelatedWork W3030541619 @default.
- W2241288537 hasRelatedWork W4281781014 @default.
- W2241288537 hasRelatedWork W4286298967 @default.
- W2241288537 hasVolume "28" @default.
- W2241288537 isParatext "false" @default.
- W2241288537 isRetracted "false" @default.
- W2241288537 magId "2241288537" @default.
- W2241288537 workType "article" @default.